Edition:
India

People: Bausch Health Companies Inc (BHC.TO)

BHC.TO on Toronto Stock Exchange

30.51CAD
8:31pm IST
Change (% chg)

$-0.42 (-1.36%)
Prev Close
$30.93
Open
$30.87
Day's High
$30.90
Day's Low
$30.13
Volume
184,509
Avg. Vol
687,230
52-wk High
$36.52
52-wk Low
$23.60

Karabelas, Argeris 

Dr. Argeris (Jerry) N. Karabelas, Ph.D., is Independent Director of the Company. He has served on the Board since June 2016. Since December 2001, Dr. Karabelas has been a Partner at Care Capital, LLC (“Care Capital”), a life sciences venture firm with $500M under management. Prior to his work at Care Capital, Dr. Karabelas was the founder and Chairman at Novartis BioVenture Fund, and served as Head of Healthcare and CEO of Worldwide Pharmaceuticals for Novartis Pharma AG. Prior to joining Novartis, Dr. Karabelas was Executive Vice President of SmithKline Beecham, where he was responsible for U.S. and European operations, regulatory and strategic marketing. Dr. Karabelas has been a director of REGENEXBIO Inc., a clinical-stage biotechnology company, since May 2015. He has also served on the board of Braeburn Pharmaceuticals, Inc., a private specialty pharmaceuticals company, since 2015, and has been the Chairman of Polyphor, LTD., a privately-held biopharmaceutical company, since June 2013. Dr. Karabelas previously served from June 2012 to June 2016 as Chairman of Inotek Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company (which merged with Rocket Pharmaceuticals, Inc. in 2017), and from 2003 to 2013 as Chairman of Vanda Pharmaceuticals, a global biopharmaceutical company.

Basic Compensation

Total Annual Compensation, USD 135,622
Restricted Stock Award, USD 250,000
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 385,622

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Joseph Papa

14,741,000

Paul Herendeen

6,400,810

Thomas Appio

4,386,600

Joseph Gordon

1,962,200

William Humphries

8,434,210

Mark McKenna

--
As Of  31 Dec 2018